| 摘要 |
PURPOSE: Provided are methods of treating conditions which present with low bone mass, particularly osteoporosis, frailty, an osteoporotic fracture, a bone defect, childhood idiopathic bone loss, alveolar bone loss, mandibular bone loss, bone fracture, osteotomy, bone loss associated with periodontitis, or prosthetic ingrowth comprising administering prostaglandin agonists which are EP4 receptor selective prostaglandin agonists. CONSTITUTION: The EP4 receptor selective prostaglandin agonist is especially a compound of formula(1) (variables are as defined in the specification). In formula(1), Q is COOR3, CONHR4 or tetrazol-5-yl; A is a single or cis double bond; B is a single or trans double bond; U is formula(2); R2 is alpha-thienyl, phenyl, phenoxy, monosubstituted phenyl and monosubstituted phenoxy, the substituents being chloro, fluoro, phenyl, methoxy, trifluoromethyl or (C1-C3)alkyl; R3 is hydrogen, (C1-C5)alkyl, phenyl or p-biphenyl; R4 is COR5 or SO2R5; and R5 is phenyl or (C1-C5)alkyl.
|
